Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Agios Pharmaceuticals (AGIO) Common Equity: 2011-2024

Historic Common Equity for Agios Pharmaceuticals (AGIO) over the last 14 years, with Dec 2024 value amounting to $1.5 billion.

  • Agios Pharmaceuticals' Common Equity fell 21.05% to $1.3 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $1.3 billion, marking a year-over-year decrease of 21.05%. This contributed to the annual value of $1.5 billion for FY2024, which is 90.00% up from last year.
  • Per Agios Pharmaceuticals' latest filing, its Common Equity stood at $1.5 billion for FY2024, which was up 90.00% from $811.0 million recorded in FY2023.
  • Agios Pharmaceuticals' 5-year Common Equity high stood at $1.5 billion for FY2024, and its period low was $399.5 million during FY2020.
  • Moreover, its 3-year median value for Common Equity was $1.1 billion (2022), whereas its average is $1.2 billion.
  • Per our database at Business Quant, Agios Pharmaceuticals' Common Equity crashed by 37.63% in 2020 and then skyrocketed by 223.40% in 2021.
  • Agios Pharmaceuticals' Common Equity (Yearly) stood at $399.5 million in 2020, then soared by 223.40% to $1.3 billion in 2021, then decreased by 14.80% to $1.1 billion in 2022, then decreased by 26.33% to $811.0 million in 2023, then soared by 90.00% to $1.5 billion in 2024.